

Adele K Fielding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4668018/publications.pdf>

Version: 2024-02-01

126
papers

9,672
citations

94433

37
h-index

37204

96
g-index

130
all docs

130
docs citations

130
times ranked

9145
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	27.0	1,443
2	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2015, 16, 57-66.	10.7	1,031
3	Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 2007, 109, 944-950.	1.4	716
4	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 111, 1827-1833.	1.4	702
5	Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 2007, 109, 3189-3197.	1.4	655
6	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	27.8	355
7	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 2017, 35, 1795-1802.	1.6	348
8	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood, 2009, 114, 5136-5145.	1.4	346
9	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood, 2014, 123, 843-850.	1.4	321
10	Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood, 2009, 113, 4489-4496.	1.4	257
11	Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. British Journal of Haematology, 1997, 98, 512-519.	2.5	230
12	Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood, 2001, 97, 3746-3754.	1.4	223
13	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	12.8	218
14	Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG 2993 trial. British Journal of Haematology, 2012, 157, 463-471.	2.5	161
15	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica, 2016, 101, 1524-1533.	3.5	154
16	Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. Blood, 2019, 134, 1415-1429.	1.4	148
17	Minimal residual disease is a significant predictor of treatment failure in non-T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. British Journal of Haematology, 2010, 148, 80-89.	2.5	147
18	IGH@ Translocations, CRLF2 Deregulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 3100-3108.	1.6	120

#	ARTICLE	IF	CITATIONS
19	Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cellâ€Depleted Allogeneic Transplantation for Hodgkin's Lymphoma. Journal of Clinical Oncology, 2011, 29, 971-978.	1.6	117
20	Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus. Journal of Virology, 2002, 76, 5051-5061.	3.4	111
21	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809.	2.4	106
22	<i>IGH</i>@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. Journal of Clinical Oncology, 2014, 32, 1453-1462.	1.6	87
23	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics, 2018, 17, 1739-1751.	4.1	87
24	An oncolytic measles virus engineered to enter cells through the CD20 antigen. Molecular Therapy, 2003, 7, 62-72.	8.2	86
25	Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Research, 2003, 63, 6463-8.	0.9	82
26	G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. British Journal of Haematology, 1997, 99, 933-938.	2.5	70
27	Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood, 2018, 131, 917-931.	1.4	68
28	Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood, 2014, 123, 1327-1335.	1.4	63
29	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 3221-3226.	1.4	61
30	Molecular classification improves risk assessment in adult <i>BCR-ABL1</i>â€negative B-ALL. Blood, 2021, 138, 948-958.	1.4	59
31	Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood, 2010, 115, 2763-2768.	1.4	58
32	Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2010, 90, 564-570.	1.0	57
33	HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood, 2010, 115, 5147-5153.	1.4	56
34	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica, 2013, 98, 945-952.	3.5	54
35	A Hyperfusogenic Gibbon Ape Leukemia Envelope Glycoprotein: Targeting of a Cytotoxic Gene by Ligand Display. Human Gene Therapy, 2000, 11, 817-826.	2.7	51
36	Characterisation of the genomic landscape of <i>CRLF2</i>â€rearranged acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2017, 56, 363-372.	2.8	49

#	ARTICLE	IF	CITATIONS
37	Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA). <i>Blood</i> , 2015, 126, 679-679.	1.4	39
38	Measles as a potential oncolytic virus. <i>Reviews in Medical Virology</i> , 2005, 15, 135-142.	8.3	38
39	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. <i>Haematologica</i> , 2009, 94, 1399-1406.	3.5	34
40	Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 640-648.	2.5	33
41	Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 8-12.	3.5	26
42	Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1234-1241.	2.0	26
43	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. <i>Leukemia</i> , 2022, 36, 625-636.	7.2	25
44	Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. <i>Blood</i> , 2014, 124, 96-105.	1.4	24
45	Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2009, 88, 1312-1318.	1.0	23
46	Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 594-602.	3.3	23
47	Differential Cytopathology and Kinetics of Measles Oncolysis in Two Primary B-cell Malignancies Provides Mechanistic Insights. <i>Molecular Therapy</i> , 2011, 19, 1034-1040.	8.2	22
48	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	8.5	22
49	Does Imatinib Change the Outcome in Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.. <i>Blood</i> , 2007, 110, 8-8.	1.4	22
50	Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function. <i>Journal of Immunology</i> , 2012, 188, 1002-1010.	0.8	20
51	Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. <i>Seminars in Hematology</i> , 2020, 57, 142-148.	3.4	20
52	Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus. <i>Molecular Therapy</i> , 2020, 28, 1043-1055.	8.2	18
53	Successful remission induction therapy with gilteritinib in a patient with <i>de novo FLT3</i>-mutated acute myeloid leukaemia and severe COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e189-e191.	2.5	17
54	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 3033-3037.	5.2	16

#	ARTICLE	IF	CITATIONS
55	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. <i>Lancet Haematology</i> , 2022, 9, e262-e275.	4.6	14
56	Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. <i>Blood</i> , 2010, 116, 169-169.	1.4	13
57	Philadelphia-Positive Acute Lymphoblastic Leukemia—Is Bone Marrow Transplant Still Necessary?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S84-S88.	2.0	12
58	The Role of Neutrophils in Measles Virus—mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF. <i>Molecular Therapy</i> , 2016, 24, 184-192.	8.2	12
59	Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 523-533.	1.4	12
60	Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	2.5	12
61	Single nucleotide polymorphism array—based signature of low hypodiploidy in acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 604-615.	2.8	12
62	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7005-7005.	1.6	12
63	First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006). <i>Blood</i> , 2021, 138, 366-366.	1.4	12
64	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. <i>Lancet Haematology</i> , 2022, 9, e276-e288.	4.6	12
65	CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. <i>Blood Advances</i> , 2020, 4, 4665-4668.	5.2	11
66	First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006). <i>Blood</i> , 2019, 134, 739-739.	1.4	11
67	Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 160-169.	2.3	10
68	Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell—origin of ALL subgroups — a UKALLXII study. <i>British Journal of Haematology</i> , 2010, 148, 394-401.	2.5	9
69	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1834-1839.	3.0	9
70	Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. <i>Frontiers in Pharmacology</i> , 2020, 11, 209.	3.5	9
71	Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14. <i>Blood</i> , 2013, 122, 3900-3900.	1.4	9
72	Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317). <i>Blood</i> , 2015, 126, 733-733.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Response: Chemotherapy or allografting for young adults with high-risk ALL?. Blood, 2008, 111, 5755-5755.	1.4	8
74	In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).. Blood, 2006, 108, 2-2.	1.4	8
75	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. American Journal of Hematology, 2016, 91, 1107-1112.	4.1	7
76	<i>IKZF1</i> alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. Blood Advances, 2021, 5, 3322-3332.	5.2	7
77	Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Frontiers in Pharmacology, 2020, 11, 1308.	3.5	7
78	Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14. Blood, 2019, 134, 288-288.	1.4	6
79	Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. Blood, 2010, 116, 524-524.	1.4	6
80	An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE® Antibody Construct Blinatumomab. Blood, 2014, 124, 3704-3704.	1.4	6
81	Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 965-965.	1.4	6
82	Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation. Blood, 2016, 128, 5985-5985.	1.4	6
83	SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome. Blood, 2014, 124, 3773-3773.	1.4	5
84	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. Blood, 2015, 126, 2618-2618.	1.4	5
85	Peripheral Blood Progenitor Cells Versus Bone Marrow. Stem Cells and Development, 1994, 3, 299-304.	1.0	4
86	Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.. Blood, 2005, 106, 1466-1466.	1.4	4
87	Comparative analysis of melphalan <i>versus</i> busulphan α cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. British Journal of Haematology, 2019, 187, e20-e24.	2.5	3
88	Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. Frontiers in Pharmacology, 2020, 11, 571066.	3.5	3
89	Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. Blood, 2010, 116, 493-493.	1.4	3
90	Antibody responses to <i>SARS-CoV-2</i> vaccination in patients with acute myeloid leukaemia and high risk <i>MDS</i> on active anti-cancer therapies. British Journal of Haematology, 2022, 198, 478-481.	2.5	3

#	ARTICLE	IF	CITATIONS
91	Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. <i>Leukemia and Lymphoma</i> , 2020, 61, 491-493.	1.3	2
92	Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1010-1012.	1.3	2
93	The Value of Molecular Monitoring for Residual Disease (MRD) in Early Morphological Remitters among Adults Diagnosed with B Cell ALL and Treated According to the MRC UKALL12 Protocol.. <i>Blood</i> , 2005, 106, 1467-1467.	1.4	2
94	The Impact of Imatinib Therapy on Adult Philadelphia Positive Acute Lymphoblastic Leukaemia (ALL): Early Results from the UKALL12/ECOG 2993 Study.. <i>Blood</i> , 2005, 106, 1839-1839.	1.4	2
95	Utility of FDG-PET/CT in Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2890-2890.	1.4	2
96	En-Abl-ing treatment of ‘Ph-like’ ALL?. <i>Blood</i> , 2019, 134, 1277-1278.	1.4	1
97	Editors’ Introduction to special issue. <i>British Journal of Haematology</i> , 2020, 191, 519-520.	2.5	1
98	Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1473-1473.	1.4	1
99	Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. <i>Blood</i> , 2019, 134, 2746-2746.	1.4	1
100	Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 112, 3314-3314.	1.4	1
101	Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial.. <i>Blood</i> , 2005, 106, 331-331.	1.4	1
102	An Optimised In Vivo Modelling System For Adult Acute Lymphoblastic Leukaemia (ALL) Enables Sensitive Detection Of Leukaemia Initiating Cells (LIC) and Drug Resistant Clones. <i>Blood</i> , 2013, 122, 2641-2641.	1.4	1
103	Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1225-1225.	1.4	1
104	Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). <i>Blood</i> , 2014, 124, 208-208.	1.4	1
105	Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO. <i>Blood</i> , 2019, 134, 3484-3484.	1.4	1
106	Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL. <i>British Journal of Haematology</i> , 2020, 191, 558-561.	2.5	1
107	JAK-ing up treatment for CRLF2-R ALL. <i>Blood</i> , 2022, 139, 645-646.	1.4	1
108	Be careful what you wish for?. <i>Blood</i> , 2007, 109, 2673-2674.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S176-S177.	0.4	0
110	65. Oncolytic Measles Virus Differentially Affects Mitochondrial Biogenesis in Transformed versus Non-Transformed BM-Derived MSCs. Molecular Therapy, 2016, 24, S28-S29.	8.2	0
111	663. Can Oncolytic Measles Virus Targeted to CD20 Recapitulate Any of the Effects of Rituximab in the Treatment of Acute Lymphoblastic Leukemia?. Molecular Therapy, 2016, 24, S262-S263.	8.2	0
112	ARF way to Ph+ ALL stratification?. Blood, 2018, 131, 1394-1395.	1.4	0
113	Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol.. Blood, 2005, 106, 1468-1468.	1.4	0
114	T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. Blood, 2008, 112, 4413-4413.	1.4	0
115	Attenuated Measles Virus: A Promising Therapeutic Modality for B Cell Malignancy.. Blood, 2009, 114, 2460-2460.	1.4	0
116	Vaccine Measles Virus Has Therapeutic Potential In B Cell Malignancy.. Blood, 2010, 116, 3757-3757.	1.4	0
117	Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma. Blood, 2011, 118, 2016-2016.	1.4	0
118	Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. Blood, 2012, 120, 663-663.	1.4	0
119	Evaluation Of IKZF1 \hat{p} 4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial. Blood, 2013, 122, 1335-1335.	1.4	0
120	Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria. Blood, 2013, 122, 1401-1401.	1.4	0
121	TP53 Alterations Are Frequent in Patients over 60 Years with B-Precursor Acute Lymphoblastic Leukemia (ALL) and Low Hypodiploid/Near Triploid (HoTr) Karyotype; They Correlate with RB1 Deletion and Leukemic Telomere Gain. Blood, 2014, 124, 3801-3801.	1.4	0
122	in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. Blood, 2015, 126, 795-795.	1.4	0
123	Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID). Blood, 2016, 128, 4681-4681.	1.4	0
124	Activation of the LMO2 Oncogene in T-ALL through a Somatically Acquired Neomorphic Promoter. Blood, 2016, 128, 733-733.	1.4	0
125	Commonly Used Chemotherapy Drugs Differentially Determine Microenvironment-Mediated Protection, Via Mitochondrial Transfer, to B-Precursor Acute Lymphoblastic Leukaemia Cells. Blood, 2018, 132, 2690-2690.	1.4	0
126	Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial. Blood, 2019, 134, 2743-2743.	1.4	0